CytomX Therapeutics, Inc.

CytomX Therapeutics Misses on EPS, Stock Up 0.82%

CytomX Therapeutics reported a loss per share of $0.52, but the stock still rose by 0.82% following the earnings announcement. The lack of revenue figures and management commentary leaves investors with limited context. The stock's positive reaction may indicate that investors were expecting a worse outcome or are optimistic about future developments.